Penumbra (PEN) Net Equity Issued and Repurchased (2017)

Penumbra (PEN) posted quarterly Net Equity Issued and Repurchased of $2000.0 for Q4 2017, up 100.67% quarter-over-quarter from -$298000.0 in Q2 2017.

Penumbra (PEN) Net Equity Issued and Repurchased (2017) Analysis & Trends

Penumbra (PEN) has reported Net Equity Issued and Repurchased for 1 consecutive years, with $2000.0 the latest figure, recorded in Q4 2017.

In Q4 2017, Net Equity Issued and Repurchased changed N/A year-over-year to $2000.0; the TTM figure through Sep 2018 stood at $2000.0 (down 100.0% YoY), while the FY2020 annual figure was $134.8 million, changed N/A from the prior year.
Net Equity Issued and Repurchased climbed to $2000.0 in Q4 2017 per PEN's latest filing, from -$298000.0 in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $106.6 million in Q1 2017 and bottomed at -$298000.0 in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	-
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	-
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	-
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	-
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	-
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	-
10	Penumbra	12.76 Bn	12.10 Bn	264.94 Mn	-

Download Data